Understanding our Scientific Commitment

Although proton beam therapy is the expanding radiotherapy treatment option of choice for cancer, its cost is currently hindering its worldwide expansion.

Application of proton therapy is also restricted by a series of unsolved technical challenges. Both the cost and technical limitations are directly traceable to dependence on legacy accelerators in the market, which are heavy, expensive, and impose technical limitations on the resulting beam.

To address these shortcomings in the field, Advanced Oncotherapy plc was created in 2012 and capitalised on the success of ADAM SA, a CERN spin-off, which was acquired in 2013.

Why?

There is a superior radiotherapy technology to treat cancer - proton therapy - but it is not widely available and up until now has been too expensive.

  • Worldwide 12 million patients could benefit proton therapy, but at the currently the capacity of all proton centres worldwide only 60,000 patients can be treated.

  • Proton therapy is available predominantly in big cities in rich countries. Our goal is to make this treatment available to everybody

How?

ADAM SA is the root of the Company. A spin-off from the renowned research institution CERN, we have a world-class team with outstanding medical, physics and commercial expertise, supported by a strong network of advisers and well-established industrial partners.

What?

AVO is developing a unique, fully integrated, proton therapy system: the LIGHT system which is expected to become the first commercially available linear proton accelerator for the medical treatment of cancer patients. AVO's LIGHT system is designed to deliver superior clinical effectiveness at a competitive cost. In addition, its modular accelerator construction allows for easier installation at any site.